25 years of recombinant proteins from reactor-grown cells — Where do we go from here?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The purpose of this review is to describe the current status and to highlight several emerging trends in the manufacture of recombinant therapeutic proteins in cultivated mammalian cells, focusing on Chinese hamster ovary cells as the major production host. Over the past 25 years, specific and volumetric productivities for recombinant cell lines have increased about 20-fold as the result of improvements in media and bioprocess design. Future yield increases are expected to come from further developments in gene delivery and genetic selection for more efficient recovery of high-producing cell lines and in high-throughput cultivation systems to simplify medium design and bioprocess development. Other emerging trends in protein manufacturing that are discussed include the use of disposal bioreactors and transient gene expression. We specifically highlight current research in our own laboratories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Self-citationReactor Engineering in Large Scale Animal Cell Culture
Nienow, A. W. (2006) · Cytotechnology · doi:10.1007/s10616-006-9005-8 · Cited by 433
Large-Scale transfection of mammalian cells for the fast production of recombinant protein
Pham, P. L., Kamen, A., & Durocher, Y. (2006) · Molecular Biotechnology · doi:10.1385/mb:34:2:225 · Cited by 236
Advances in animal cell recombinant protein production: GS-NS0 expression system
Barnes, L. M., Bentley, C. M., & Dickson, A. J. (2000) · Cytotechnology · doi:10.1023/a:1008170710003 · Cited by 129
Kwaks, T. H. J., Barnett, P., Hemrika, W., Siersma, T., Sewalt, R. G. A. B., Satijn, D. P. E., Brons, J. F., van Blokland, R., Kwakman, P., Kruckeberg, A. L., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt814 · Cited by 126 · cited 1×
“Furthermore, DNA elements like scaffold/matrix attachment regions (S/MARs), insulators, antirepressor elements, and ubiquitous chromatin opening elements (UCOEs) have been shown to support stable protein production in recombinant cell lines (Stief et al., 1989; Zahn-Zabal et al., 2001; Kwaks et al., 2003; Williams et…”
Background
Cited by
Kim, J. Y., Kim, Y.-G., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3758-5 · Cited by 801
Human cells: new platform for recombinant therapeutic protein production
Swiech, K., Picanço-Castro, V., & Covas, D. T. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.04.023 · Cited by 178
Perspectives for clinical use of engineered human host defense antimicrobial peptides
Pachón-Ibáñez, M. E., Smani, Y., Pachón, J., & Sánchez-Céspedes, J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux012 · Cited by 159
Druz, A., Son, Y., Betenbaugh, M., & Shiloach, J. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2012.12.004 · Cited by 73
“…and g/L recombinant protein titers rely on media and process optimization coupled with site-specific integration of recombinant DNA and efficient cell screening (Hacker et al. 2009; Kim et al. 2012), miRNAs engineering approach described here can be complementary to these industrial techniques.”
BackgroundMethodReliable protein production in a Pseudomonas fluorescens expression system
Retallack, D. M., Jin, H., & Chew, L. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2011.09.010 · Cited by 46
Metadata
- Authors
- Hacker, D. L., De Jesus, M., & Wurm, F. M.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 27
- Issue
- 6
- Pages
- 1023-1027
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W1967142377
- Cited by
- 177
- References
- 6
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 25 years of recombinant proteins from reactor-grown cells — Where do we go from here? https://app.cochat.ai/papers/10.1016/j.biotechadv.2009.05.008
- The paper
- Hacker, D. L., De Jesus, M., & Wurm, F. M. (2009). 25 years of recombinant proteins from reactor-grown cells — Where do we go from here? Biotechnology Advances. https://doi.org/10.1016/j.biotechadv.2009.05.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.